Literature DB >> 22147770

Chronic myeloid leukemia: the basis of treatment for tomorrow.

Angelo M Carella, John M Goldman, Giovanni Martinelli, Junia V Melo, Danilo Perrotti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22147770      PMCID： PMC3232252          DOI： 10.3324/haematol.2011.052571

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  19 in total

1.  The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.

Authors:  R Salgia; E Quackenbush; J Lin; N Souchkova; M Sattler; D S Ewaniuk; K M Klucher; G Q Daley; S K Kraeft; R Sackstein; E P Alyea; U H von Andrian; L B Chen; J C Gutierrez-Ramos; A M Pendergast; J D Griffin
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

2.  The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

Authors:  Paolo Neviani; Ramasamy Santhanam; Rossana Trotta; Mario Notari; Bradley W Blaser; Shujun Liu; Hsiaoyin Mao; Ji Suk Chang; Annamaria Galietta; Ashwin Uttam; Denis C Roy; Mauro Valtieri; Rebecca Bruner-Klisovic; Michael A Caligiuri; Clara D Bloomfield; Guido Marcucci; Danilo Perrotti
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

3.  Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.

Authors:  A K Samanta; S N Chakraborty; Y Wang; H Kantarjian; X Sun; J Hood; D Perrotti; R B Arlinghaus
Journal:  Oncogene       Date:  2009-02-23       Impact factor: 9.867

4.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

5.  CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.

Authors:  Linhua Jin; Yoko Tabe; Sergej Konoplev; Yuanyuan Xu; Clinton E Leysath; Hongbo Lu; Shinya Kimura; Akimichi Ohsaka; Mary-Beth Rios; Leslie Calvert; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Mol Cancer Ther       Date:  2008-01       Impact factor: 6.261

6.  Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia.

Authors:  Chen Zhao; Alan Chen; Catriona H Jamieson; Mark Fereshteh; Annelie Abrahamsson; Jordan Blum; Hyog Young Kwon; Jynho Kim; John P Chute; David Rizzieri; Michael Munchhof; Todd VanArsdale; Philip A Beachy; Tannishtha Reya
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

7.  Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

Authors:  Thomas O'Hare; Michael W N Deininger; Christopher A Eide; Tim Clackson; Brian J Druker
Journal:  Clin Cancer Res       Date:  2010-11-22       Impact factor: 12.531

8.  BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

Authors:  Mhairi Copland; Francesca Pellicano; Linda Richmond; Elaine K Allan; Ashley Hamilton; Francis Y Lee; Roberto Weinmann; Tessa L Holyoake
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

9.  Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.

Authors:  Mhairi Copland; Ashley Hamilton; Lucy J Elrick; Janet W Baird; Elaine K Allan; Niove Jordanides; Martin Barow; Joanne C Mountford; Tessa L Holyoake
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

10.  Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.

Authors:  Christine Dierks; Ronak Beigi; Gui-Rong Guo; Katja Zirlik; Mario R Stegert; Paul Manley; Christopher Trussell; Annette Schmitt-Graeff; Klemens Landwerlin; Hendrik Veelken; Markus Warmuth
Journal:  Cancer Cell       Date:  2008-09-09       Impact factor: 31.743
View more
  3 in total

Review 1.  Allogeneic stem cell transplantation for chronic myeloid leukemia.

Authors:  Jiří Pavlů; Jane F Apperley
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

2.  Structure, regulation, signaling, and targeting of abl kinases in cancer.

Authors:  Oliver Hantschel
Journal:  Genes Cancer       Date:  2012-05

3.  What challenges remain in chronic myeloid leukemia research?

Authors:  Angelo M Carella; Susan Branford; Michael Deininger; Francois X Mahon; Giuseppe Saglio; Anna Eiring; Jamshid Khorashad; Thomas O'Hare; John M Goldman
Journal:  Haematologica       Date:  2013-08       Impact factor: 9.941
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.